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ABSTRACT
A Study of  “Correlation Between Absolute Eosinophil Count And
Asthma Control In Adult Patients In Govt Royapettah Hospital,
Chennai-14”
Introduction :
Bronchial Asthma is one of the most common disorders of
inflammatory reactions of the respiratory tract, characterized by
breathlessness, wheezing, minimal cough and expectoration.
Aim:
To study  the correlation of absolute eosinophil count  with asthma
control in adult
Methods and methodology:
This study was conducted on the patient who attended the Asthma
op in Govt Royapettah Hospital, Kilpauk Medical College, Chennai.  The
patients of 18-75 years were selected for the study. Both the sexes were
included and who belong to different socio-economic groups was taken as
per inclusion criteria. A total of 40 cases were selected minimum of study
was 6months. The statistical analysis made here is based on the data
obtained from 40 cases.
Results :
Fifty seven and half percent (57.5%%) of the asthmatic had
increased eosinophil count(more than 450 cell per cumm) and forty two
and half percent (42.5%) had  normal absolute eosinophil count and p
value 0.000.
Conclusion :
Our study shows that serum absolute eosinophil count  have a
significant    impact(p value 0.000) on   asthma control, higher levels
correlating with poor control ,so increased dose or frequent steroid
inhalation and dose adjustment, lower absolute eosinophil count well
control of asthma.
Measurement of absolute eosinophil count can be useful in
assessing the severity of such inflammation. So the evaluation of absolute
eosinophil count is a useful baseline investigation and its serial
measurements can be taken as a marker for adjusting the dose of inhaled
steroids.
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1INTRODUCTION
Asthma has an alarmingly increasing incidence in the past few
decades1and is one of the leading causes of morbidity in adults. Bronchial
Asthma is a very common chronic disorder of the airways which affects
individuals at almost any age and is an important cause of respiratory
morbidity and mortality. The World health organization estimate is that
there are 15 to 20 million people with asthma in India and affects 7% of
the population and 300 million people worldwide2
Bronchial asthma is a predisposition to chronic inflammation of the
lungs in which the bronchi are reversibly narrowed3It creates a substantial
burden on individuals and families as it is more often under diagnosed &
undertreated. Though effective screening, evaluation and management
strategies are well established in developed countries, these are not fully
implemented in India.  Thus asthma appears to be increasing in
prevalence despite considerable improvements in management and
numerous drugs for treatment of asthma. So, it is essential to study the
role of other extraneous factors influencing the control of asthma.  There
is various Allergens concern everyone, since it has become the part and
parcel of life due to various factors involved. To an extent, no one is
spared by allergens in atmosphere in which we live. All this allergens will
precipitate the condition, leading to exacerbations of asthma where the
2smooth muscle cells in the bronchi constrict the airways and become
inflamed and swollen thereby breathing become difficult.
In modern system of medicine, drugs are used for long term
prevention, starting with inhaler, corticosteroids and then long acting ?-2
agonists if necessary.
Absolute eosinophil count is shown to be a risk factor for allergic
asthma and can be used as a marker of disease severity in adult with
asthma4.So, in the present study our aim was to study of correlation
between absolute eosinophil count and asthma control in adult patients5.
These have prompted me to known a clinical study of Absolute
Eosinophil count in bronchial asthma and to evaluate the effectiveness of
medicine.
3REVIEW OF LITERATURE
Framework:
1. Historical aspects of bronchial asthma
2. Magnitude of asthma in adults
3. Definition of asthma
4. Classificationof asthma
5. Pathogenesis
6. Absolute eosinophil count and its role in asthma
7. Diagnosis of asthma
8. Management of asthma
1. Historical aspects:
Asthma, though known for centuries is still an intriguing disease.
The term asthma was derived from Greek word “casein” meaning sharp
breath or to exhale with open mouth. This term was first used in Homer’s
epic poem ‘Iliad’ in 800 B.C. It was called ‘sacred disease’ that was
earned from a visit of gods. The word first appears in Homer’s “Iliad”.
Hippocrates was the first to use it as a medical term in ‘corpus
4hippocraticum’6in 450BC.In the 17th century, ‘Bernardino Ramazzini7’,
identified and noted a connection between asthma and organic dust. In
19th century, initially it was considered as psychosomatic illness and was
treated based on psychoanalysis. Later Henry Hyde Salter in his treatise
“on asthma & its treatment” has refined the term asthma as “Paroxysmal
dyspnoea of a peculiar character with intervals of healthy respiration
between attacks.” He found that aduquate amount of theobromine content
in black coffee gives relief in asthmatic spasms.8At the end of 19th
century physicians concluded that asthma was a distinct disease with
specific manifestations.
DEVELOPMENT OF THE RESPIRATORY SYSTEM:
At about four weeks of development, the respiratory tracts  begins
as an elongated outgrowth of the foregut. “This out growth is called as the
respiratory diverticulum9”.The respiratory diverticulum have endodermal
lining and its gives rise to the epithelium and glands of the trachea,
bronchi and alveoli ducts and sac . The Musles, connective tissue and
cartilage, in “relation to the organs of respiration are derived from
splanchnopleuric mesoderm10”.
As the diverticulum elongates, its distal end form the tracheal bud.
It divides into bronchial buds.
5By 24weeks, respiratory bronchioles will develop11. During
6to16weeks, lungs will be formed, except those of gaseous exchange.
During 16 to 26 weeks, lung tissue becomes highly vascular and
respiratory bronchioles, alveolar ducts and alveoli develop12.
At 30th week, mature alveoli develop before birth, remaining will
develop afterbirth. Infants13 born before this time tend to exhibit infant
respiratory distress syndrome resulting from inadequate surfactant
production. During fetal life, the lungs are filled with fluid and all
respiratory exchanges are made by the placenta. Vascular shunts cause
circulating blood to largely bypass the lungs. At birth, the filled fluid
pathway empties, and therespiratory passageways are filled with air. As
the PCO2 in the baby’s blood rises, the respiratory centres are excited,
causing the baby to take its first breath. “The alveoli becomes inflate and
begins to function in gas exchange, but it is nearly two weeks before the
lungs are fully inflated14”.
RESPIRATORY SYSTEMFUNCTIONAL ANATOMY:
“The respiratory system contents upper respiratory tract and lower
respiratory tract, They are the nose and nasal cavity, pharynx, larynx,
trachea, bronchi and their smaller branches, and the lungs, which contain
the terminal air sacs, or alveoli15”. Functionally, the system consists of
two zones. The respiratory zone, the actual site of gaseous exchange, is
6composed of the respiratory bronchioles, alveolar ducts, and alveoli, all
of which are microscopic structures16. The conducting zone contain  all
other respiratory passage, which provides fairly rigid conduits for air to
reach the gas exchange sites.
Conducting Zone Structures:
The right and left main (primary) bronchi are formed by the
division of the trachea approximately at the level of T7 in an erect
position. Each bronchus runs obliquely in the mediastinum before
plunging into the medial depression (hilum) of the lung on its own side.
The right main bronchus is shorter , wider and more vertical than the left
and is the more common site for an inhaled foreign object to become
lodged17. By the time incoming air reaches the bronchi, it is warm,
cleansed of mostpathogenes, dust, and saturated with water vapour.
Once inside the lungs, each main bronchus subdivided into lobar
(secondary) bronchi,and then lungs had three on the right and two on the
leftlober bronchi and then each are supplying one lung lobe. The lobar
bronchi branch into third-order segmental (tertiary) bronchi, which divide
repeatedly into smaller and smaller bronchi (fourth-order, fifth-order,
etc.). Overall, there are about around 23 orders of branching air passages
in the lungs. Smaller passages are more than 0.1 cm in diameter are called
bronchioles (“little bronchi”), and the tiniest of these, the terminal
7bronchioles, are less than 0.05 cm in diameter. Because of this branching
pattern, “the conducting network within the lungs is often called the
bronchial or respiratory tree18”.
Respiratory Zone Structures:
 It is composed of a respiratory bronchioles, alveolar ducts,
atria,sac and alveoli. There are about more than “300 million alveoli in
the two lungs19“and each alveolus has an average diameter of about 0.02
centimetres. The alveolar walls are extremely very thin and between the
alveoli is an almost solid networks of interconnecting capillaries.
The Respiratory Membrane:
The walls of the alveoli are composed primarily of a single layer of
squamous epithelial cells, called type I cells, surrounded by a basement
membrane. The alveoli external surfaces are densely covered with a
“cobweb” of pulmonary capillaries. Together, “the alveolar and capillary
walls and their fused basement membranes form the respiratory
membrane, a 5-µm-thick air-blood barrier that has gas on one side and
blood flowing past on the other”.
8Gas exchanges occur mainly  by simple diffusion across the
respiratory  Membrane,(o2) oxygens passes from the alveolus into the
blood and CO2 leaves the blood to enter the gas-filled alveolus.
2. Magnitude of asthma:
Asthma has become an increasingly common problem with a
global prevalence of 1-18% in different countries. It is estimated that
around 300million people, worldwide, suffer from asthma. The
prevalence increases by 50% every decade.
Studies show that the prevalence of asthma in Asian countries is
around 2-4% as compared to high prevalence in countries like United
Kingdom, Canada, Australia, New Zealand and other developed
countries. The economic burden of asthma is estimated to be 1% of all
9disability adjusted life year (DALY) lost worldwide. A worldwide
increase in the prevalence of asthma is being reported at an alarming rate
of 5% per year. In India the estimated prevalence is 5-10%.20
           Asthma may have its onset at any age before puberty and is twice
more common in boys in the pre pubertal age21. But the sex ratio
equalized by age 30. Fifty percent of all asthmatic children are
asymptomatic from 10-20 years of age but recurrences are common in
adulthood.
 The cost of treating asthma in patients  places a considerable
burden on the health resources owing to the cost of medications,
hospitalizations and the time spent by parents or caretakers in looking
after them.
BRONCHIAL ASTHMA
3.Definition:
The manner in which asthma has been defined has changed
significantly over time.
? In 1950’s asthma was defined as a disease characterized by airflow
obstruction that could resolve spontaneously or following therapy22
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? In 1960’s asthma was viewed as an episodic disease in which
airflow obstruction was caused by bronchial hyper
responsiveness23.
? In 1970’s the concept of preventing bronchospasm and managing
disease progression was considered.
? In 1990’s asthma was redefined as a chronic inflammatory disease
characterized by reversible airflow obstruction and bronchial hyper
responsiveness.24
Asthma is “a chronic inflammatory disorder of the airways in
which many cells and cellular elements play a vital role, in particular the
mast cells, eosinophils, T lymphocytes, macrophages, epithelial cells
,other inflammatory mediator25.” In susceptible individuals, the
inflammation causes recurrent episodes of wheezing mainly early
morning, breathlessness, chest tightness and cough mainly dry in nature
particularly at night or in the early morning. These symptoms are usually
associated with widespread but variable airway obstruction that is often
reversible either spontaneously or with treatment. “The inflammation also
causes an  increase in the existing bronchial hyper responsiveness to a
variety of stimuli”. 26
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Asthma can be classified as
Three groups based on etiology
? Atopic (IgE mediated, triggered by allergens),
? Non Atopic (non IgE mediated, triggered by infection),
? Mixed and exercise or aspirin induced
ALLERGIC ASTHMA
Asthma is characterized by paroxysmal attacks of difficulty in
breathing Accompanied by a sense of suffocation. In between the
episodes the patient is symptom-free. An asthmatic attack can be
provoked by a variety of factors which include allergens, emotional
factors, physical strain, infections and exposure to sudden changes in
temperature, climate and weather factors.
Allergy  is  said  to  be  the  cause  in  a  significant  percentage  of
asthmatic population. Allergy to chemicals, drugs, dust-mites, pollens,
moulds, animal-dander, food items and insect bites/stings etc. can
provoke an asthmatic attack. In most of the cases of asthma, typical type
1 reaction is seen. Thus ‘asthma is a variable obstructive but reversible
disease which affects the air passages.
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PREVALENCE:
An estimated 20 million Americans suffer from asthma, and 50%
of asthma cases are “Allergic asthma”. “About one half of the cases
develop before age of 18 and another third occur before age 40”27.
ALLERGEN INDUCED ASTHMA:
                 In atopic asthmatic individuals with experimental inhalation of
allergen leads to development of different types of reaction.
Immediate asthma (early reaction)
Airflow limitation begins within minutes of contact with the
allergen, reaches its maximum in around 15-20 minutes and subsides
byarounds 1 hour.
Dual and Late Phase reactions:
Following an immediate reaction many asthmatics develop more
prolonged and sustained attack of airflow limitation that responds less
well to inhalation ofbronchodilator drugs. Isolated late phase reactions
with no preceding immediate responsecan occur after the inhalation of
some occupational sensitizers, like isocyanates.
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Recurrent asthmatic reactions:
The development of the late phase reaction is associated with an
increase in the underlying level of airway hyper-responsiveness such that
individuals may showcontinuing episodes of asthma on subsequent
days28.
ETIOLOGY:
Etiology factors of asthma are of two types. Some factors, called
inducing factors cause initial development of asthma, whereas some other
factors provoke an episode inpredisposed individuals suffering from
asthma and these are called provoking factor or triggerfactors29.
INDUCING FACTORS:
Genes:
Genetic factors are important inducing factors, where atopic
individuals go in to risk factor for developing allergic asthma. A distinct
gene for atopy on chromosome 5q,11q and 12q has been identified30.
PREDISPOSING FACTORS:
Allergens:
Exposure to a specific allergen will precipitate an attack of asthma,
particularly in young people having asthma. House dust mite is the
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commonest allergen. Pollens, molds, animal dander and cockroaches are
other common allergens provoking asthma. This typeof asthma is named
as ‘allergic asthma’.
Infection:
It is well recognized that viral infections commonly cause attacks
of asthma. Secondary bacterial infection is widely held to occur and
perpetuate the inflammatory reactions which give rise to prolonged
airway narrowing31.
Environment:
Many patients with allergic asthma experience worsening of
symptoms on contact with cigarette smoke, car exhaust fumes, strong
perfumes or high concentrations of dust in atmosphere.
Allergic asthma exacerbations increase in both summer and winter,
air pollution, episodes associated with climate temperature inversions,
NO2 in presence of high concentrations in summer, No2 and So2 in the
winter32.
Occupation:
Its  exposure to chemical agents (such as epoxyresins in
plasticFactories or toluene diisocyanate in varnishes and paints) that
either induces bronchoconstriction directly or via degranulation of mast
15
cells. This is called occupational asthma. It is characterized by a cyclic
history, with symptoms becoming prominent towards the end of a work
shift and an increase of symptoms after leaving the work site33.
Exercise:
It is provoked by various forms of exercise such as running or
climbing stairs34.
Food:
Among Indians, ice and cola drink are reported to be more
sensitive and causes bronchoconstriction. In some cases egg, milk and
wheat also act as a triggering factor for allergic asthma35.
Psychological Factors:
It is well known  emotional factors may been influence asthma, but
there is no evidence that patients with the disease are any more
psychologically disturbed than theirnon-asthmatic peers36.
Nocturnal:
It refers to attacks that predominantly occur during the night. It has
been related to recumbency, a diminished mucociliary clearance,
nocturnal airway cooling, exposure tonight time allergens, gastro
esophageal reflex and a ‘morning dip’ in circulatingepinephrine and
cortisol.
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Drugs:
Beta blocking drugs, cholinergic drugs used for myasthenia gravis,
and Prostaglandins (PGF2) usedforinducingabortion and drug induce
gastritis areknowntoinduced bronchoconstriction37.
NON ATOPIC ASTHMAOR IDIOSYNCRATIC ASTHMA38:
It  also called as Intrinsic or late – onset asthma.
A significant fraction of patients with asthma present with no
family or personal history of allergy, with  skin tests was negative and
with normal serum levels of IgE and therefore have disease that cannot be
classified on the basis of currently defined immunological mechanisms.
These patients are said to have idiosyncratic asthma or non-Atopic
asthma.
Non-Atopic asthma, is divided into two groups
i. Mechanical obstruction groups
ii. Bacterial infection groups
It is essential to having a clear idea of the  immunological
fundamentals, if one has to offer optical treatment to patients with allergic
asthma, because this disease is partly due to the harmful effects of the
immune system.
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5. Pathophysiology:
The complex mechanisms involved in pathophysiology of asthma
include:
1. Airway inflammation
2.  Intermittent airflow obstruction
3.  Airway  hyper responsiveness
Asthma Pathogenesis
            Airway narrowing is the final common pathway for all the
symptoms and physiological changes in  asthma. Many factors are
associated with narrowing of airways.
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Airway obstruction is mainly due to
? Edema and inflammation reponses of mucous membrane lining the
airways
? Increased secretions of mucus and inflammatory cells
? Contraction in the smooth muscles of bronchi
?
           Airway obstruction is usually diffuse but not uniform. In many
adults with asthma, both larger and smaller airways are obstructed,
though some patients may have exclusive smaller airway disease.
           Airway obstruction results in increased resistance to airflow and
decreased flow rates contributing to hyperinflation. Overinflated lungs
compensate for pulmonary obstruction to some extent, but when the tidal
volume exceeds the pulmonary dead space, it leads to alveolar
hypoventilation.
             The pulmonary blood flow is affected in hyperinflation because
of increased intra alveolar and intra pleural pressure leading to uneven
pulmonary circulation. Thus increased intra alveolar pressure along with
decreased ventilation and perfusion, leads to V-P (ventilation-perfusion)
mismatch in various lung units.
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Ultimately all these factors contribute to the development of
hypoxia. CO2 retention occurs only in the later stages when the
obstruction is more severe.
HYPERSENSITIVITY
Immunologic tissue injury in response of allergen exposure.
Classified in to following types are
1) Type 1 immediate or reaginic
2) Type 2 cytotoxic
3) Type 3 IgG or IgM mediated
4) Type 4 antibody dependent cell mediated cytotoxicity
5) Type 5 stimulatory/ blocking reactions
Mechanisms39
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Type 1 Hypersensitivity pathophysiology
Clinical classification
Four groups based on frequency of symptoms,number of time
emergence visit and hospitilization, severity of attack and pulmonary
function tests abnormality
1) Intermittent asthma
2) Persistent asthma
3) Acute exacerbation: mild, moderate, severe asthma,
4) Specialvariants: there are 5 types
a) Cough variant asthma
b) Exercise induced asthma,
c) Occupational asthma,
d) drug-induced asthma (aspirin, other NSAID, beta
blocker
e) Seasonal asthma
21
Pathophysiological mechanisms at the level of molecule:
Inhalation of allergens leads to biphasic response by early and late phases
EARLY LATE
1.Occurs in 30 min-2 hour
2.Mast cell degranulation and
release of preformed mediators
3.Histamine, LTC4, D4, E4,
Platelet
Activating factor.
4.Broncho constriction
1. Occurs in 6-8 hrs.
2. Release of cytokines & newly
generated
Mediators.
3.Eosinophilic cationic protein,
eosinophilic chemotactic factor.
4. Continued airway hyper
responsiveness,
Mucus secretion and
vasodilatation.
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6. Diagnosis of asthma:
CLINICAL EVALUATION OF ASTHMA:
HISTORY:
? The key to the detection and clinical evaluation of asthma is a
careful history. Notonly can the physician usually elicit a
description of symptoms that are sufficiently characteristic to make
a diagnosis, but it may be possible to obtain important information
about agents that is responsible for worsening symptoms, so that
they can be avoided.
? Physician also establishes trusting relationship with the patient, so
that therapeuticprogram will be followed by the positive effect of
the physician’s optimism and reassurance.
PRESENTING SYMPTOMS:
Characteristically patients with asthma have some combination of
dyspnoea, wheeze, chest tightness, cough – symptoms may follow
exposure to specific agents such as inhaled (or) ingested antigens (or)
viral infection. More often symptoms develop without identifiable cause.
One of the most common features is development (or) worsening of
symptoms at night. It is known that both normal people and asthmatic
patients have circadian rhythms of peak expiratory flow rate (PEFR) –
PEFR lowest between 3 and 6 am. So patients wake up in morning with
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symptoms mainly wheezing and breathing difficulty, nocturnal cough in
asthma patients.
Dyspnoea:
Shortness of breath is extremely common but not invariable
complaint of patients with asthma. It is likely related to the scene of effort
for ventilation and function of the severity of airway obstruction.
Dyspnoea is paroxysmal and most commonly occur late night. The
patient may be restless agitated, anxious, sweating, orthopnoic and
tachypnoeic, breathing through pursed lips with a prolonged expiration
and using accessory muscles of respiration.
Wheeze:
The high velocity of flow through narrowed large airways produces
wheeze which is often first audible to the physician. Many patients may
not have wheeze during periods of asthma, but its absence should not
exclude consideration of diagnosis.
Tightness:
One of the characteristic symptoms of asthma is the sense of chest
tightness. Patient commonly volunteer that their symptoms are associated
with this sensation of tightness. It is likely that this sensation reflects the
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excessive activity of the vagal receptors known to be a fundamental
feature of asthma.
Cough:
         Cough is usually non-productive, frequently associated with
expectoration ofmucoid sputum, at times quite frothy and liquid.
Upper Airways Symptoms:
              Although asthma is primarily a disorder of the intrathoracic
airways, some patients do indicate that their symptoms originate in the
region of larynx. There are evidences that this is narrowing of the extra
thoracic upper airways in asthma and that may contribute to the reduction
of inspiratory and expiratory flow rate. Although this may not be a
frequent cause of flow limitation in patients, inspiratory stridor may be
present in asthma or may be the presenting complaint and needs to be
evaluated.
ACUTE SEVERE ASTHMA / STATUS ASTHMATICUS:
It is life-threatening emergency that places the patient at risk of
develop ingrespiratory failure. Patients are severely dyspnoeic, cyanosed
and often moribund. Any patient of asthma may develop acute severe
asthma, as a complication. It may be precipitated by infection, allergic
factors or psychological stress. Even in mild cases such paroxysms may
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supervene without warning. The attacks usher in either as progressive
worsening of an existing paroxysm or sudden onset of severe dyspnoea
and air hunger in a mild or moderate asthmatic.
Widening of intercostal spaces, decrease in lateral expansion of the
chest, tachynoea, tachycardia and fatigue are features of asthma during
attack. And decrease in cardiac output, pulses paradoxus, tachycardia,
hypoxemia, respiratory acidosis are features of asthma during severe
attack.
Physical Examination:
i) Position of patient in which shoulder girdle is fixed.
ii) Accessory respiratory muscles are actively involved in
respiration.
iii) The chest is held in near to end inspiratory position.
iv) Percussion note may be unaltered or it may become hyper
resonant with Progression of disease.
v) Breath sounds will be obscure with lots of added sounds,
rhonchi.
vi) Expiration will be prolonged.
vii) In chronic cases, the chest may be pigeon shaped.
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CHRONIC ASTHMATIC:
(i) Chest is barrel shaped
(ii)  Shoulders are rounded,
(iii)  Usually the patient is of small stature,
(iv) Usually the patient breathes from his mouth,
(v) He/She is a daily wheezer (He coughs more at night with varying
amounts of mucous and plugs).
LABORATORY INVESTIGATION:
Blood for Absolute Eosinophil Count:
       It one of components of white blood cells is called eosinophils, in the
blood, where there is increase in eosinophils  in the circulating blood is
called eosinophilia.it ranges from 1-6% of eosinophils and 40-450/cumm
of absolute eosinophil count40.
It is calculated by percentage of eosinophils multiplied by the
white blood cell count to give the absolute eosinophil count.
Significance:
         Eosinophilia is common in bronchial asthma regardless of whether
allergic factors can be shown to have an etiologic role. In many
asthmatics, the degree of eosinophils may correlate with the severity of
asthma.
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Other blood investigations finding includes,
        Leucocytosis, indicates infection, serum IgE levels will also be high.
But these are not specific for asthma, until and unless other infections are
ruled out.
Sputum Examination:
A wet preparation of sputum of many asthmatic patients contains
spiral casts (Curschmann’s spirals), eosinophilia and Charcot Leyden
crystals. Presence of sputumand blood eosinophilia is suggestive of the
diagnosis of asthma41.
X-ray chest:
Usually normal x-ray
It may show hyper-inflation. It also reveals complications of severe
asthma such As Rib fracture, Pneumothorax and Pneumo mediastinum.
Arterial blood gas Analysis:
Respiratory alkalosis followed by hypoxia with severe respiratory
distress, compromises the PCO2 and PH become normal, finally
respiratory acidosis develops with hypercapnia and severe hypoxia.
Increase in PCO2 level is a bad prognosis.This for to assess the severity
for asthma.
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Pulmonary Function Test42:
It’s also lung function test are useful in assessing the functional
status of the respiratory system both in physiological and pathological
condition.
Types
1) Static lung function tests
Based on volume of air that flow in to or out of lungs.
2) Dynamiclung function test
Based on time ,i.e. the rate at which air flows into or out of lungs.
LUNG VOLUMES:
1) Tidal volume
2) Inspiratory reserve volume
3) Expiratory reserve volume
4) Residual volume
LUNG CAPACITIES:
1) Inspiratory capacity
2) Vital capacity
3) Functional residual capacity
4) Total lung capacity
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Spirogram :
It is the graphical record of lung volumes and capacities using
spirometer. Upward deflection of the spirogram denotes inspiration and
the downward curve indicates expiration.
Disadvantages :
Volume, which cannot be measured by spirometry, is the residual
volume.
Plethysmography
It is a technique used to measure all the lung volumes and
capacities.
Measurement of functional residual capacity and residual volume:
1) Helium dilution technique
2) Nitrogen washout method
3) Plethysmography
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Tables show to diagnosis restrictive and obstructive lesion.
31
This diagram shows variable pattern of airway diseases.
32
During the attack, the lung volume is reduced; with a decrease in
the forced vitalcapacity (FVC); the maximal mid expiratory flow rates
(MMF) and the forced expiratory volume in one second (FEV1).The
FEV1 / FVC ratio is usually less than 75%. The RV/TLC ratio increased
owing to air trapping.
1. Skin Sensitivity Testing’s:
These tests are done to find out the possible allergens to which he
or she is Allergic. A small quantity of allergen is put on skin which is
pricked. In positive cases, a wheal is seen at the site after 20-40 minutes
of introduction of the allergens in minute doses, in skin by pricking the
skin.
2. Radio-Allergosorbent Test (R.A.S.T.):
The importance of these tests comes to play when dermal reactivity
tests are Inconclusive. In allergic individuals, the levels of IgE are raised,
when exposed to allergens. When skin reactivity tests are inconclusive,
one can come to significant Conclusion by measuring IgE specific to
individual allergens by RAST.
3. Challenge tests:
a. Allergen / antigen challenge tests:
Challenge or provocation tests are more accurate then the above
stated tests.
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These tests are done in emergency. The antigens are introduced
through inhalation with the help of a nebulizer. Within few minutes (7 to
15 minutes) in positive cases, there will be a fall of 20% or more in FEV1
PEFR indices.
b. Exercise challenge tests:
In positive cases there is a decrease in FEV and PEFR indices after
physical Exercises. This decrease is of about 20% of more and is
maximal 5-10 minutes, after exercise and recovers to normal over a
course of time of 30-60 minutes13.
Though asthma is diagnosed by clinical symptomatology, lung
function tests are helpful in supporting the diagnosis in doubtful cases
and also for monitoring the control of asthma.
Grading and classification of Asthma:
1. Grading of Severity of Asthma
Grading can be done based on
(1) Symptoms of air flow obstruction
(2) Night symptoms
(3) Peak expiratory flow rate (personal best and diurnal
variation).
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Based on the severity, asthma   can be graded as:
Grade 1:  Mild intermittent asthma
Grade 2:  Mild persistent asthma
Grade 3:  Moderate persistent asthma
Grade 4:  Severe persistent asthma
Classification based on severity43 GINA
Classification Days withSymptoms
Nights with
symptoms PEFR
PEFR
variability (%)
Mild
intermittent
<2/week <2/month >80% <20%
Mild persistent >2/week
but <1/day >2/month >80% 20-30%
Moderate
persistent
Daily >1/week 60-80% >30%
Severe
persistent
Continuous Frequent <60% >30%
Assessment of control of asthma (GINA guidelines 2012)
Asthma control was categorized as uncontrolled, partly controlled and
controlled as per guidelines by Global Initiative for Asthma Guidelines.
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In particular, the levels asthma control were defined depending on
the presence/absence of daytime symptoms, limitation of activities,
nocturnal symptoms/awakening, need for reliever/rescue treatment, and
FEV1  /PEFR results in the last four weeks.
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Assessment and monitoring
1. Asthma Clinic examination
2.  Lung function testing
        • Spirometry
        • Peak expiratory flow monitoring
PEFR is the maximum flow rate generated during a forceful
expiration. PEFR primarily reflects large airway flow. FEV over one
second is a dynamic measure of flow used in formal spirometry.
Although peak flow rate usually correlate well with FEV1, this correlation
decreases in patients with asthma as airflow limitation is diminishes.
Daily PEFR monitoring may assist the early changes in asthma that
may require therapy, evaluating responsiveness to changes in therapy and
giving a quantitative measurement of improvement.
PEFR was pioneered by Martin Wright for assessing lung function.
Peak expiratory flow (PEF) monitoringdevices provide a simple
and inexpensive tool used to measure airflow at home.   Children aged 5
and above are able to use a peak flow meter. PEFs vary in their ability to
detect airflow obstruction. In some patients, PEF declines only when
airflow obstruction is severe. So it is advisable to monitor PEF by
measuring morning and evening PEFs. Best of three consecutive attempts
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should be noted as the final value. Variation in PEF >20% between
morning and evening value is consistent with the diagnosis of asthma.
Procedure for using Peak Flow Meter:
1. Move the indicator to the bottom of the numbered scale.
2. Patient is asked to stand up and take a deep breath,airflow
filling the lungs
3. Mouth piece is placed in the mouth and the patient is asked
to firmly close his   lips around it without putting the tongue
inside the hole.
4. Then the patient is asked to blow out as hard and fast as
possible in a single blow. The value should be written down.
The steps 1 to 4 should be repeated 2 more times to get the
personal best peak flow reading
PEAK FLOW METER
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Predicted PEFR values according to height in male:
Ht (cm) PEFR(Lt/min)Boys Ht (cm)
PEFR(Lt/min)
Boys Ht (cm)
PEFR(Lt/min)
Boys
101 120 134 235 167 351
102 123 135 239 168 354
103 127 136 242 169 358
104 130 137 246 170 361
105 134 138 249 171 365
106 137 139 253 172 368
107 141 140 256 173 372
108 144 141 260 174 375
110 148 142 263 175 379
111 151 143 267 176 382
112 155 144 270 177 386
113 158 145 274 178 389
114 162 146 277 179 393
115 165 147 281 180 396
116 169 148 284 181 400
117 172 149 288 182 403
118 176 150 291 183 407
119 179 151 295 184 410
120 183 152 298 185 414
121 186 153 302 186 417
122 190 154 305 187 421
123 193 155 309 188 424
124 197 156 312 189 428
125 200 157 316 190 431
126 204 158 319 191 435
127 207 159 323 192 438
128 211 160 326 193 442
129 214 161 330 194 445
130 218 162 333 195 449
131 221 163 337 196 452
132 225 164 340 197 456
133 228 165 344 198 459
134 232 166 347 199 463
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Predicted PEFR values for according to height in female
Ht (cm)
PEFR (lt/min)
Girl
Ht (cm)
PEFR
(lt/min)
Girl
Ht (cm)
PEFR (lt/min)
Girl
101 116 134 225 167 334
102 120 135 229 168 337
103 123 136 232 169 341
104 126 137 235 170 344
105 130 138 238 171 347
106 133 139 242 172 351
107 136 140 245 173 354
108 139 141 248 174 357
110 143 142 252 175 361
111 146 143 255 176 364
112 149 144 258 177 367
113 153 145 262 178 370
114 156 146 265 179 374
115 159 147 268 180 377
116 163 148 271 181 380
117 166 149 275 182 384
118 169 150 278 183 387
119 172 151 281 184 390
120 176 152 285 185 394
121 179 153 288 186 397
122 182 154 291 187 400
123 186 155 295 188 403
124 189 156 298 189 407
125 192 157 301 190 410
126 196 158 304 191 413
127 199 159 308 192 417
128 202 160 311 193 420
129 205 161 314 194 423
130 209 162 318 195 427
131 212 163 321 196 430
132 215 164 324 197 433
133 219 165 328 198 436
134 222 166 331 199 440
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Asthma were divided into three groups depending on levels of
control (GINA guidelines 2012)
Characteristics Controlled (All ofthe following)
Partly controlled
(Any  measure
present)
Uncontrolled
Daytime symptoms None (twice or
less/week)
More than
twice/week
Three of
more features
of partly
controlled
Limitation of activities None Any
Nocturnal symptoms
/awakening
None Any
Need for reliever/
rescue treatment
None (twice or
less/week)
More than
twice/week
Lung function (PEFR) Normal <80%predicted or
personal best(if
known)
7. Role of EOSINOPHIL in Asthma
Chronic airway inflammation as evidences by cellular infiltration
of airway by activated t lymphocytes, mast cells and macrophages and
mainly eosinophils and other mediators. Eosinophils are white blood cells
and immune system components responsible and also control
mechanisms associated with allergy and asthma.
The eosinophil is a specialized cell of the immune system first
recognized by “Paul Ehrlich” approximately 130 years ago. The
eosinophil a nucleus with two lobes, and cytoplasm filled with
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approximately more than 200 large granules containing enzymes and
proteins with variable functions.
Eosinophils are one of the components of white blood cell, where
there is increase in eosinophils in the circulating blood called
eosinophilia.it ranges from 1-6% of eosinophils and 40-450/cu mm of
absolute eosinophil count.
It is calculated by percentage of eosinophils multiplied by the
white blood cell count to give the absolute eosinophil count.
Eosinophils increased in parasite infection, allergy, asthma, etc. Its
are response for disintegration, detoxification, removal of foreign proteins
and other inflammatory responses.
Mechanism of action of eosinophils
Eosinophils are neither markedly motile nor phagocytic like the
neutrophils. Still eosinophil attack them by some special type of cytotoxic
substances present in their granules. The lethal and released at the time of
exposure to parasite or foreign protein are
1) eosinophil peroxidase: this enzyme is capable of destroying
helminths, bacteria and tumour cells.
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2) Major basic protein (MBP): Very active against helminths.its
causing distension (ballooning) and detachment of
tegumental sheath (skin like covering) of these organisms.
3) Eosinophil cationic protein (ECP): This substance is major
destroyer of helminths and 10 times more toxic than MBP.
It’s also neurotoxin.
4) Eosinophil-derived neurotoxin: its destroys the nerve fibre
mainly myelinated nerve fibers.
5) Cytokine: like IL-4,IL-5 accelerate inflammatory responses.
Diagram of eosinophil
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Mechanism of eosinophil:
8. Management of asthma:
Goals of therapy:
Themain goals for the prevention and management of asthma are
as follows:
1. Preventing chronic and troublesome symptoms, such as
coughing  or breathlessness at night, in the morning or after
exertion.
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2. Maintaining nearly normal pulmonary function.
 3. Maintaining normal activity levels (including exercise).
4. Preventing recurrent exacerbation and minimizing the need
for  emergency care and hospitalization.
Successful management of asthma patient depends on various factors
1. Asthma exhibits considerable heterogeneity with respect to
ethology, clinical presentation, severity, and response to therapy.
So it is very difficult standardize the management protocol. Each
patient requires  tailor made management strategies, depending on
the symptoms.
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2. Asthmatic have varying degrees of symptomatology at different
points of time hence a close monitoring is required for appropriate
adjustment of therapy.
Management of asthma practically divided into two parts
A. Non pharmacological therapy
B. Pharmacological therapy
A. Non pharmacological therapy
Recent studies suggest that educating the patient /parent about the
disease along with measures to implement environmental control
programs are very effective in reducing asthma morbidity and mortality.
Education:
Counselling the patients about nature of the disease and the
importance of compliance for its successful management has rendered
fruitful results.
Environmental control:
In adults who remain symptomatic despite intense therapy,
measures to control environmental triggers like avoidance of aero
allergens, air pollution, some drugs have helped in long term remission.
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Vaccination:
Inactivated influenza vaccine may safely be given to asthmatic , in
order to reduce asthma exacerbations.
Immunotherapy:
Allergen immunotherapy also appears to be of benefit in some
patients with defined allergic triggers.
Pharmacological therapy
Medications
1. Corticosteroids
Inhaled corticosteroids are the mainstay of treatment for long term
control of asthma. Glucocorticoids are not bronchodilators but reducing
bronchial hyperreactivity, inflammatory effect like antigen: antibody
reaction, mucosal edema, other trigger stimuli
Inhaled corticosteroids (ICS):
Beclamethasonedipropionate, Triamcinolone acetonide,
Budesonide, Flunisonide, Fluticasone,Ciclesonide .
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Systemiccorticosteroids:
hydrocortisone, prednisolone, dexamethasone,etc
it’s useful in severe chronic asthma, statusasthmaticus/acute severe
asthma
2. Leukotriene antagonists.
It is usually given as an add on therapy with low dose ICS in
insufficiently controlled patients. Drugs are Montelukast, Zafirlukast,
3. Short acting and Long acting inhaled beta 2 agonists
In asthmatic  who are not controlled adequately on  medium dose
ICS, this drug can be used as an  add on therapy. But mono therapy on
long term basis is best avoided. Long acting beta agonists preferably used
inhalation form.
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? Short durations are epinephrine, isoetharine, isoproterenol
? Intermediate duration are salbutamol, terbutaline,
metaproterenolalbuterol, pirbuterol, bitolterol, fenoterol, etc.
? long duration are salmeterol, formoterol, etc.
4. AntiIgE (omalizumab)
This recently introduced drug is shown to be effective in moderate
and severe persistent asthma .dose 30-700 iu/ml based on IgE level
5. methylxanthines
a. oral theophylline
b. IV Aminophylline
6. Anticholinergics:
Ipratropium bromide by MDI,mainly useful in drug induced
asthma e.g. Beta blockers
7. Lipoxygenase inhibitor:
Zileuton 600mg qid reserved for severe asthma.
8. Alternative medication:
Methotrexate, cyclosporine, tacrolimus, mycophenolate mofetil,
Reliever medications:
Rapidly acting inhaled beta 2 agonists and oral short acting beta 2
agonists are used in acute episodes. Rapidly acting inhaled beta 2 agonists
are most effective bronchodilators for the relief of acute symptoms.
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Pregnant Women
Pregnant women with  asthma  must control the disease and  ensure
a good supply of oxygen to their babies. Poor asthma control also the risk
of preeclampsia, and also develops high blood pressure and proteinuria.
Poor asthma control  increases the risk of   low birth weight.
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Differential diagnosis for asthma:
1) Its may be Airway Foreign Body, but localized sign and symptoms
2) Its may be Allergic reaction
3) Its may be Alpha1-Antitrypsin Deficiency, its main associated with
COPD
4) Aspergillosis,fungal infection with high eosinophil levels
5) Bronchiectasis, Its associated with productive sputum with postural
Chances and  signs
6) its can be Bronchiolitis
7) Chronic Obstructive Pulmonary Disease, similar to asthma.
8) its may be Churg-Strauss Syndrome
9) its can be Cystic Fibrosis
10) Gastrooesophageal Reflux Disease, main associate with peptic
ulcer diseases
11) Heart Failure its associate with sign and symptoms
12) Pulmonary Embolism  its associate with cardiac or renal or other
precipitating  factors
13) its may be Pulmonary Eosinophilia associated with increased
eosinophils count, sputum eosinophilia, worm infection
14) it’s may be Sarcoidosi, Its can be Sinusitis, Upper Respiratory
Tract  Infection, etc,
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This tables show Different between asthma and COPD
52
AIM OF THE STUDY
Aim:
To study the correlation of absolute eosinophil count  with asthma
control in adult
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MATERIALS AND METHODOLOGY
a) Study design:
Cross sectional  study
b) Place:
Asthma Clinic,
Govt Royapettah Hospital,
Kilpauk Medical College, Chennai
c) Period of study:
April 2014 to September 2014
d)  Study population:
Aged 18 to 75 years attending asthma clinic.
e) Sample size: 40 patients
f) Inclusion criteria:
All patients with asthma, aged 18 to 75 years.
g) Exclusion criteria:
1. pulmonarytuberculosis, drug allergy patients,
2. acute infections, chronic inflammatory disorders, chronic
systemic diseases and malignancies
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3. Immunocompromide state,
4. cardiac failure, pulmonary edema, pulmonary embolism,
COPD,
5. Systemic Fungal infection, worm infestation, etc
h) Methodology:
1. All  asthma patients aged between 18 to 75 years .
2. Detailed history and clinical examination was done.
3.  Peak expiratory flow rate (PEFR) was measured by using peak
flow meter.
4.  Asthma control was assessed based on the parameters of GINA
guidelines.
5. Informed consent was obtained and blood samples were taken for
measuring serum absolute eosinophil count.
6. Under strict aseptic precautions, 5 ml of venous blood was drawn.
7. Absolute eosinophils count in peripheral blood.
8.  Data entry form was filled, data was analyzed and statistical
significance of the result was determined.
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i) Statistical analysis
1. One way Anova followed by TUKEYHSD method for quantitative
variables
2. Chi square test for qualitative variable
3. Correlation was done.
4. Based on this data statistical significance was determine
56
PROFORMA
1. SR. No.
2. Name:
3. Age:
4. Sex:
5. Address:
6. Occupation
7. Chief Complaints:
i. Cough /wheeze
ii. Nighttime symptoms and awakening
iii. Daytime symptoms
iv. Limitation of activities
v. Need for reliever medications
8. Similar complaints in the past:
9.  Hospitalisation: ----times
10. Emergency visit: ----times
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11. Seasonal variation: Yes/No
12. Sleep disturbed due to cough, breathlessness: Yes/No
13. Nature of attack: After exercise/ Cough/ Cold/ Associated with
fever.
14.  Associated conditions: Rhinosinusitis/ GERD/ obesity
15. Socio economic condition
16. Precipitating  factors
Allergen
Indoor : Domestic mites, cockroach,
Furredanimals (dogs, cats, mice)
Outdoor: Pollens, fungi, molds, yeasts
Infections (predominantly viral)
Occupational
Diet
Tobacco smoke (active and passive)
Indoor/outdoor air pollution
Strong odours(perfumes), Smoke, mosquito repellents
17. EXAMINATION
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GENERAL EXAMINATION
- Built & nourishment:
- Height:                   weight:                     BMI:
- P/I/CY/CL/LN/PE
- VITALS- PR.BP,RR,TEMPERATURE
 SYSTEMIC EXAMINATION
? RESPIRATORY SYSTEM
? Inspection   :
? Palpation     :
? Percussion   :
? Auscultation:
? Cardiovascular system
? Central nervous system
? Abdominal system
18. Investigations:
? X – Ray chest
? Spirometry /PEFR
? ECHO
? Sputum microscopic exam
?  Absolute eosinophil count
19. Asthma medications
20. CONTROLLED/PARTLY CONTROLLED/UNCONTROLLED
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RESULTS
Chart : 1 - Sex distribution with level of asthma control
Levels of Asthma Control
Total
Uncontrolled
Partly
controlled
Controlled
Se
x
M
al
e
Count 6 5 10 21
% within
Sex
28.6% 23.8% 47.6% 100.0%
% within
Levels of
Asthma
Control
50.0% 41.7% 62.5% 52.5%
Fe
m
al
e
Count 6 7 6 19
% within
Sex
31.6% 36.8% 31.6% 100.0%
%with in
levels of
Asthma
control
50.0% 58.3% 37.5% 47.5%
Total
Count 12 12 16 40
% within Sex 30.0% 30.0% 40.0% 100.0%
% within Levels
of Asthma
Control
100.0% 100.0% 100.0% 100.0%
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Totally 40 patients, male 21, female 19 uncontrolled asthma 6 for
male 6 for female. Partly controlled male 5, female 7.
Impression: Absolute eosinophil count more than 450 cells per
cumm seen in 2/3 of patients. (uncontrolled and partially controlled).
Sex wise difference: male-sum of uncontrolled and partly
controlled(11) equal to controlled group(10).Female- sum of uncontrolled
and partly controlled (68%)(13) 2 times greater than controlled group(6)
(32%).
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Chart 2 : Chi-Square Tests
Value Df Asymp. Sig.(2-sided)
Pearson Chi-Square 1.236(a) 2 .539
Likelihood Ratio 1.246 2 .536
Linear-by-Linear
Association .511 1 .475
N of Valid Cases 40
A 0 cells (.0%) have expected count less than 5. The minimum
expected count is 5.70.
Chart 3 : This show male ,female sex with levels of asthma control
Sex
FemaleMale
C
ou
nt
11
10
9
8
7
6
5
4
Levels of Asthma Con
Uncontrolled
Partly controlled
Controlled
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Chart - 4 :  This show socio  economic status with levels of asthma
control  Equal in both social economic status.
Levels of Asthma Control
Total
Uncontro
lled
Partly
controlled
Contr
olled
So
ci
o 
ec
on
om
ic
 st
at
us
Lo
w
Count 8 5 7 20
% within Socio
economic status
40.0% 25.0% 35.0% 100.0%
% within Levels of
Asthma Control
66.7% 41.7% 43.8% 50.0%
H
ig
h
Count 4 7 9 20
% within Socio
economic status
20.0% 35.0% 45.0% 100.0%
%within levels of
asthma control 33.3% 58.3% 56.3% 50.0%
Total Count 12 12 16 40
% within Socio
economic status
30.0% 30.0% 40.0% 100.0%
% within Levels of
Asthma Control
100.0% 100.0% 100.0% 100.0%
Chart 5  :  Chi-Square Tests
Value df Asymp. Sig. (2-sided)
Pearson Chi-Square 1.917(a) 2 .384
Likelihood Ratio 1.945 2 .378
Linear-by-Linear
Association 1.272 1 .259
N of Valid Cases 40
A 0 cells (.0%) have expected count less than 5. The minimum
expected count is 6
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Chart 6 : This show level of asthma control with low and high social
economic status. High social economic  and low social economic are
equal disturbance with level of asthma control
Socio eosinomic status
HighLow
C
ou
nt
10
9
8
7
6
5
4
3
Levels of Asthma Con
Uncontrolled
Partly controlled
Controlled
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Chart 7 :  This tables show relation between Precipitating factor with
Levels of Asthma Control
Levels of Asthma Control
TotalUncontrol
led
Partly
controlled
Control
led
N
il
Count 0 5 8 13
% within
Precipitating factor .0% 38.5% 61.5% 100.0%
% within Levels of
Asthma Control .0% 41.7% 50.0% 32.5%
Pe
t a
ni
m
al
s
Count 3 3 4 10
% within
Precipitating factor 30.0% 30.0% 40.0% 100.0%
% within Levels of
Asthma Control 25.0% 25.0% 25.0% 25.0%
V
ira
l i
nf
ec
tio
ns
Count 2 1 1 4
% within
Precipitating factor 50.0% 25.0% 25.0% 100.0%
% within Levels of
Asthma Control 16.7% 8.3% 6.3% 10.0%
M
os
qu
ito
 re
pe
lle
nt
s Count 3 1 2 6
% within
Precipitating factor 50.0% 16.7% 33.3% 100.0%
% within Levels of
Asthma Control 25.0% 8.3% 12.5% 15.0%
Count 3 2 1 6
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Pollens % within
Precipitating factor 50.0% 33.3% 16.7% 100.0%
% within Levels of
Asthma Control 25.0% 16.7% 6.3% 15.0%
Smoke
Count 1 0 0 1
% within
Precipitating factor 100.0% .0% .0% 100.0%
%with in levels of
asthma control 8.3% 0% 0% 2.5%
Total
Count 12 12 16 40
% within
Precipitating factor 30.0% 30.0% 40.0% 100.0%
% within Levels of
Asthma Control 100.0% 100.0% 100.0% 100.0%
This chart show precipitating factor with asthma control.
Precipitating factors are pet animals, mosquito repellants, viral infections,
pollens, smoke.
1) pet animals - 10(3*3*4)(25%)
2) mosquito repellents - 6(3*1*2)(15%)
3) viral infections            - 4(2*1*1)(10%)
4) pollens                         - 6(3*2*1)(15%)
5) smoke                          - 1(1*0*0)(2.5%)
Out of 40 patients,
1) 27 had precipitating factors (67.5%),
2) 13 had no precipitating factors (32.5%)
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CHART 8 : Chi-Square Tests
Value df
Asymp. Sig. (2-
sided)
Pearson Chi-Square 11.704(a) 10 .305
Likelihood Ratio 15.419 10 .118
Linear-by-Linear
Association 8.182 1 .004
N of Valid Cases 40
A 17 cells (94.4%) have expected count less than 5. The minimum
expected count is .30.
CHART 10 :  This show  allergens 67.5%, nil precipitating factor
12.5%, Allergen mainly pet animals in city cultures compares with
rurals (25%)
Precipitating factor
Smoke
Pollens
Mosquito repellants
Viral infectins
Pet animals
Nil
C
ou
nt
10
8
6
4
2
0
Levels of Asthma Con
Uncontrolled
Partly controlled
Controlled
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CHART 11 : This table show X ray chest with  Levels of Asthma
Control.
Levels of Asthma Control
TotalUncontrol
led
Partly
controlled
Controlle
d
C
he
st
 x
 r
ay
N
or
m
al
Count 4 12 16 32
% within X
ray chest
12.5% 37.5% 50.0% 100.0%
% within
Levels of
Asthma
Control
33.3% 100.0% 100.0% 80.0%
H
yp
er
in
fla
tio
n
Count 8 0 0 8
% within X
ray chest
100.0% .0% .0% 100.0%
% with in
levels of
asthma
control
66.7% .0% .0% 20.0%
Total
Count 12 12 16 40
% within X
ray chest
30.0% 30.0% 40.0% 100.0%
% within
Levels of
Asthma
Control
100.0% 100.0% 100.0% 100.0%
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Chart  12 : Chi-Square Tests
Value Df Asymp. Sig. (2-sided)
Pearson Chi-Square 23.333(a) 2 .000
Likelihood Ratio 24.756 2 .000
Linear-by-Linear
Association 17.098 1 .000
N of Valid Cases 40
A  3 cells (50.0%) have expected count less than 5. The minimum
is 2.40.
CHART 13   : This show  relation between x ray chest and level of
asthma control.
Normal x ray chest  - 32(80%)
Hyperinflation chest x ray- 8(20%) mainly uncontrolled patients
Normal chest x ray had 32 mainly controlled group-16(40%),partly
controlled -12(30%)uncontrolled  -4 (10%)
X ray chest
HyperinflationNormal
C
ou
nt
18
16
14
12
10
8
6
4
2
Levels of Asthma Con
Uncontrolled
Partly controlled
Controlled
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CHART14 : Sputum microscopic examination with Levels of Asthma
Control
Levels of Asthma Control
TotalUncontrolled
Partly
controlled Controlled
Sp
ut
um
 e
xa
m
in
at
io
n N
or
m
al
Count 1 0 11 12
% within
Sputum
microscopic
8.3% .0% 91.7% 100.0%
% within Levels
of Asthma
Control
8.3% .0% 68.8% 30.0%
Eo
sn
op
hi
ls
Count 11 12 5 28
% within
Sputum
microscopic
39.3% 42.9% 17.9% 100.0%
% with in level
of asthma
control
91.7% 100.0% 31.3%  70.0%
Total Count 12 12 16 40
% within
Sputum
microscopic
30.0% 30.0% 40.0% 100.0%
% within Levels
of Asthma
Control
100.0% 100.0% 100.0% 100.0%
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Chart - 15 : Chi-Square Tests
Value df
Asymp. Sig. (2-
sided)
Pearson Chi-Square
19.266(a) 2 .000
Likelihood Ratio 22.110 2 .000
Linear-by-Linear
Association 13.027 1 .000
N of Valid Cases 40
3 cells (50.0%) have expected count less than 5. The minimum
expected count is 3.60.
CHART 16 : This show relation between sputum microscopic
examinations  with level of asthma control
1) normal sputum examination  -12 (30%) mainly controlled
group(27.5%)
2) Sputum eosinophilia               - 28(70%)
A) Controlled group - 5 (12.5%)
B) Partly controlled group  - 12 (30%)
C) Uncontrolled group      - 11 (27.5%)
Sputum microscopic
EosinophilsNormal
C
ou
nt
14
12
10
8
6
4
2
0
Levels of Asthma Con
Uncontrolled
Partly controlled
Controlled
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CHART 17 : This table show ECHO  with  Levels of Asthma Control
Levels of Asthma Control
TotalUncontrolled
Partly
controlled
Controlled
EC
H
O
N
or
m
al
Count 6 12 16 34
% within
ECHO
17.6% 35.3% 47.1% 100.0%
% within
Levels of
Asthma
Control
50.0% 100.0% 100.0% 85.0%
M
ild
 p
ul
m
on
ar
y 
hy
pe
rte
ns
io
n Count 6 0 0 6
% within
ECHO
100.0% .0% .0% 100.0%
% within
levels of
asthma
control
50.0% .0% .0% 15.0%
Total
Count 12 12 16 40
% within
ECHO
30.0% 30.0% 40.0% 100.0%
% within
Levels of
Asthma
Control
100.0% 100.0% 100.0% 100.0%
This tables shows normal echo study in 34 patients (85%), mild
pulmonary hypertension in 6 (15%).
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Table 17 : Chi-Square Tests
Value df
Asymp. Sig. (2-
sided)
Pearson Chi-Square 16.471(a) 2 .000
Likelihood Ratio 17.181 2 .000
Linear-by-Linear
Association 12.069 1 .001
N of Valid Cases 40
3 cells (50.0%) have expected count less than 5. The minimum
expected count is 1.80.
CHART - 18
ECHO 1) Normal study           - 34 (85%)
2) mild pulmonary HT - 6 (15%) mainly uncontrolled group
ECHO
Mild pulmonary hyperNormal
C
ou
nt
18
16
14
12
10
8
6
4
Levels of Asthma Con
Uncontrolled
Partly controlled
Controlled
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CHART 19 : Absolute eosinophil count with Levels of Asthma
Control
Levels of Asthma Control
TotalUncontr
olled
Partly
controlled
Controlle
d
A
B
SO
LU
TE
 E
O
SI
N
O
PH
IL
 C
O
U
N
T
< 
45
0
Count 0 1 16 17
% within Absolute
eosinophil count
.0% 5.9% 94.1% 100.0%
% within Levels of
Asthma Control
.0% 8.3% 100.0% 42.5%
> 
45
0
Count 12 11 0 23
% within Absolute
eosinophil count
52.2% 47.8% .0% 100.0%
%within levels of asthma
control
100.0% 91.7%% 0% 57.5%
Total Count 12 12 16 40
% within Absolute
eosinophil count
30.0% 30.0% 40.0% 100.0%
% within Levels of
Asthma Control
100.0% 100.0% 100.0% 100.0%
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Table 20 : Chi-Square Tests
Value df Asymp. Sig. (2-sided)
Pearson Chi-Square 36.249(a) 2 .000
Likelihood Ratio 47.664 2 .000
Linear-by-Linear
Association 29.560 1 .000
N of Valid Cases 40
0 cells (.0%) have expected count less than 5. The minimum
expected count is 5.10.
CHART - 21
These show 40 patients had
1) Absolute eosinophil count less than 450    -17 (42.5%)
2) Absolute eosinophil count more than 450  -23 (57.5%)
Absolute eosinophil count
> 450<= 450
C
ou
nt
20
10
0
Levels of Asthma Con
Uncontrolled
Partly controlled
Controlled
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CHART 18
One way Descriptive
Age in years
N Mean Std.Deviation
Std.
Error
95% Confidence
Interval for Mean
Minimum Maximum
Lower
Bound
Upper
Bound
Uncontrolled 12 34.33 8.574 2.475 28.89 39.78 23 52
Partly
controlled 12 33.42 5.418 1.564 29.97 36.86 22 42
Controlled 16 37.44 10.302 2.575 31.95 42.93 20 54
Total 40 35.30 8.549 1.352 32.57 38.03 20 54
ANOVA
CHART 19
Age in years
Sum of
Squares df
Mean
Square F Sig.
Between
Groups 126.879 2 63.440 .862 .431
Within
Groups 2723.521 37 73.609
Total 2850.400 39
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CHART - 20
One way  -Descriptives
Weight in kg
N Mean
Std.
Deviatio
n
Std.
Error
95% Confidence
Interval for Mean
Mini
mum
Maxi
mum
Lower
Bound
Upper
Bound
Uncontrolled 12 63.50 12.072 3.485 55.83 71.17 46 86
Partly
controlled
12 60.67 9.039 2.609 54.92 66.41 44 76
Controlled 16 67.06 10.529 2.632 61.45 72.67 45 80
Total 40 64.08 10.683 1.689 60.66 67.49 44 86
CHART 21
ANOVA
Weight in kg
Sum of
Squares df
Mean
Square F Sig.
Between
Groups 286.171 2 143.085 1.271 .292
Within
Groups 4164.604 37 112.557
Total 4450.775 39
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CHART 22
Oneway
Descriptives : Height
N Mean Std.Deviation
Std.
Error
95% Confidence
Interval for Mean
Minimu
m
Maximu
m
Lower
Bound
Upper
Bound
uncontrolled 12 165.75 5.643 1.629 162.16 169.34 156 174
Partly controlled 12 160.50 7.728 2.231 155.59 165.41 146 170
Controlled 16 166.56 4.546 1.136 164.14 168.98 160 174
Total 40 164.50 6.397 1.011 162.45 166.55 146 174
CHART – 23
ANOVA
Height
Sum of
Squares df
Mean
Square F Sig.
Between
Groups 278.813 2 139.406 3.916 .029
Within
Groups 1317.188 37 35.600
Total 1596.000 39
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CHART - 24 - Post Hoc Tests:Multiple Comparisons -Dependent
Variable: Height -Tukey HSD
(I) Levels of
Asthma
Control
(J) Levels of
Asthma
Control
Mean
Difference
(I-J)
Std. Error Sig.
95% Confidence
Interval
Lower
Bound
Upper
Bound
Uncontrolled Partly
controlled 5.25 2.436 .093 -.70 11.20
Controlled -.81 2.279 .932 -6.38 4.75
Partly
controlled
Uncontrolled -5.25 2.436 .093 -11.20 .70
controlled -6.06(*) 2.279 .030 -11.63 -50
Controlled Uncontrolled .81 2.279 .932 -4.75 6.38
Partly
controlled 6.06(*) 2.279 .030 .50 11.63
? The mean difference is significant at the .05 level.
CHART 24 : Homogeneous Subsets Height-Tukey HSD
Levels of Asthma Control N
Subset for alpha = .05
1 2
Partly controlled 12 160.50
Uncontrolled 12 165.75 165.75
Controlled 16 166.56
Sig. .076 .935
Means for groups in homogeneous subsets are displayed.
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CHART 26 : Hospitalisation * Levels of Asthma Control
Levels of Asthma Control
Total
Uncontrolle
d
Partly
controlle
d
Controlle
d
H
O
SP
IT
A
LI
ZA
TI
O
N
0 Count 0 3 8 11
% within
Hospitalisation
.0% 27.3% 72.7% 100.0%
% within Levels of
Asthma Control
.0% 25.0% 50.0% 27.5%
1
Count 2 7 8 17
% within
Hospitalisation
11.8% 41.2% 47.1% 100.0%
% within Levels of
Asthma Control
16.7% 58.3% 50.0% 42.5%
2
Count 3 2 0 5
% within
Hospitalisation
60.0% 40.0% .0% 100.0%
% within Levels of
Asthma Control
25.0% 16.7% .0% 12.5%
3
Count 7 0 0 7
% within
Hospitalisation
100.0% .0% .0% 100.0%
%within level of
asthma control 58.3% .0% 0% 17.5%
Total Count 12 12 16 40
% within
Hospitalisation
30.0% 30.0% 40.0% 100.0%
% within Levels of
Asthma
100.0% 100.0% 100.0% 100.0%
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CHART 27 : Chi-Square Tests
Value df
Asymp. Sig.
(2-sided)
Pearson Chi-Square 29.077(a) 6 .000
Likelihood Ratio 34.448 6 .000
Linear-by-Linear
Association 22.183 1 .000
N of Valid Cases 40
CHART 28
Hospitalisation
3210
C
ou
nt
9
8
7
6
5
4
3
2
1
Levels of Asthma Con
Uncontrolled
Partly controlled
Controlled
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CHART - 29 : Emergency visit * Levels of Asthma Control
Levels of Asthma Control
Total
Uncontrolle
d
Partly
controlled
Controlled
EM
ER
G
EN
C
Y
 V
IS
IT
0 Count 0 2 14 16
% within Emergency
visit
.0% 12.5% 87.5% 100.0%
% within Levels of
Asthma Control
.0% 16.7% 87.5% 40.0%
1
Count 2 8 2 12
% within Emergency
visit
16.7% 66.7% 16.7% 100.0%
% within Levels of
Asthma Control
16.7% 66.7% 12.5% 30.0%
2
Count 8 2 0 10
% within Emergency
visit
80.0% 20.0% .0% 100.0%
% within Levels of
Asthma Control
66.7% 16.7% .0% 25.0%
3
Count 2 0 0 2
% within Emergency
visit
100.0% .0% .0% 100.0%
%  within  levels  of
asthma control 16.7% .0% .0% 5.0%
Total Count 12 12 16 40
% within Emergency
visit
30.0% 30.0% 40.0% 100.0%
% within Levels of
Asthma
100.0% 100.0% 100.0% 100.0%
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CHART 30 : Chi-Square Tests
Value df Asymp. Sig. (2-sided)
Pearson Chi-Square 40.514(a) 6 .000
Likelihood Ratio 44.226 6 .000
Linear-by-Linear
Association 27.746 1 .000
N of Valid Cases 40
11 cells (91.7%) have expected count less than 5. The minimum
expected count is .60.
CHART 31
Emergency visit
3210
C
ou
nt
16
14
12
10
8
6
4
2
0
Levels of Asthma Con
Uncontrolled
Partly controlled
Controlled
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CHART 32 : Oneway : Descriptives
PEFR
N Mean Std.Deviation
Std.
Error
95%
Confidence
Interval for
Mean Minimum Maximum
Lower
Bound
Upper
Bound
uncontrolled 12 184.25 15.088 4.356 174.66 193.84 160 200
Partly
controlled 12 260.33 29.137 8.411 241.82 278.85 200 290
Controlled 16 346.56 21.062 5.265 335.34 357.79 310 378
Total 40 272.00 71.877 11.365 249.01 294.99 160 378
CHART 33
ANOVA
PEFR
Sum of
Squares df
Mean
Square F Sig.
Between
Groups 182987.146 2 91493.573
183.01
8 .000
Within
Groups 18496.854 37 499.915
Total 201484.000 39
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CHART - 34 Post Hoc Tests:Multiple Comparisons
Dependent Variable: PEFR
Tukey HSD
(I) Levels of
Asthma
Control
(J) Levels of
Asthma
Control
Mean
Difference
(I-J)
Std.
Error
Sig.
95% Confidence Interval
Lower
Bound
Upper
Bound
Uncontrolled Partly
controlled
-76.08(*) 9.128 .000 -98.37 -53.80
Controlled
-162.31(*) 8.538 .000 -183.16 -141.47
Partly
controlled
Uncontrolled
76.08(*) 9.128 .000 53.80 98.37
Controlled -86.23(*) 8.538 .000 -107.08 -65.38
Controlled Uncontrolled 162.31(*) 8.538 .000 141.47 183.16
Partly
controlled
86.23(*) .8.538 .000 65.38 107.08
*  The mean difference is significant at the .05 level.
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CHART 35 : Homogeneous Subsets:PEFR
Tukey HSD
Levels of Asthma Control N
Subset for alpha = .05
1 2 3
Uncontrolled 12 184.25
Partly controlled 12 260.33
Controlled 16 346.56
Sig. 1.000 1.000 1.000
Means for groups in homogeneous subsets are displayed.
a Uses Harmonic Mean Sample Size = 13.091.
b  The group sizes are unequal. The harmonic mean of the
group sizes is used. Type I error levels are not guaranteed.
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CHART 36 : Oneway
Descriptives : Normal PEFR
N Mean
Std.
Deviatio
n
Std.
Error
95% Confidence
Interval for Mean Minim
um
Maxi
mumLower
Bound
Upper
Bound
Uncontr
olled
12 338.58 26.092 7.532 322.01 355.16 298 375
Partly
controll
ed
12 319.58 32.523 9.388 298.92 340.25 265 361
Controll
ed
16 343.25 21.306 5.326 331.90 354.60 311 375
Total 40 334.75 27.747 4.387 325.88 343.62 265 375
CHART 37 : ANOVA:Normal PEFR
Sum of
Squares df
Mean
Square F Sig.
Between
Groups 4092.667 2 2046.333 2.920 .066
Within
Groups 25932.833 37 700.887
Total 30025.500 39
87
CHART 38 :Post Hoc Tests:Multiple Comparisons
Dependent Variable: Normal PEFR :Tukey HSD
(I) Levels of
Asthma
Control
(J) Levels of
Asthma
Control
Mean
Difference
(I-J)
Std.
Error
Sig.
95% Confidence
Interval
Lower
Bound
Upper
Bound
Uncontrolled Partly
controlled
19.00 10.808 .198 -7.39 45.39
Controlled
-4.67 10.110 .890 -29.35 20.02
Partly
controlled
Uncontrolled
-19.00 10.808 .198 -45.39 7.39
controlled -23.67 10.110 .062 -48.35 1.02
Controlled Uncontrolled 4.67 10.110 .890 -20.02 29.35
Partly
controlled
23.67 10.110 .062 -1.02 48.35
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CHART 39
Homogeneous Subsets : Normal PEFR : Tukey HSD
Levels of Asthma Control N
Subset for alpha = .05
1
Partly controlled 12 319.58
Uncontrolled 12 338.58
Controlled 16 343.25
Sig. .070
Means for groups in homogeneous subsets are displayed.
a  Uses Harmonic Mean Sample Size = 13.091.
b  The group sizes are unequal. The harmonic mean of the group sizes
is used. Type I error levels are not guaranteed.
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CHART 39 : Oneway : Descriptives : PEFR Percentage
N Mean Std.Deviation
Std.
Error
95% Confidence
Interval for Mean
Minimu
m
Maximu
m
Lower
Bound
Upper
Bound
Uncontrolle
d
12 54.5487 4.31305
1.2450
7
51.8083
57.289
1
47.48 64.31
Partly
controlled
12 81.4276 4.03905
1.1659
7
78.8613
83.993
9
75.47 87.58
Controlled
16
100.982
9
1.59778 .39945
100.131
5
101.83
43
98.16 105.92
Total
40 81.1860 19.74730
3.1223
2
74.8706
87.501
5
47.48 105.92
CHART40
ANOVA : PEFR Percentage
Sum of
Squares df
Mean
Square F Sig.
Between
Groups 14785.908 2 7392.954
647.62
4 .000
Within
Groups 422.374 37 11.416
Total 15208.282 39
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CHART 41 : Post Hoc Tests:Multiple Comparisons
Dependent Variable: PEFR Percentage :Tukey HSD
(I) Levels of
Asthma
Control
(J) Levels of
Asthma
Control
Mean
Difference
(I-J)
Std.
Error
Sig.
95% Confidence
Interval
Lower
Bound
Upper
Bound
Uncontrolled Partly
controlled
-26.8789(*) 1.37934 .000 -30.2465 -23.5112
Controlled
-46.4342(*) 1.29026 .000 -49.5843 -43.2840
Partly
controlled
Uncontrolled
26.8789(*) 1.37934 .000 23.5112 30.2465
Controlled -19.5553(*) 1.29026 .000 -22.7054 -16.4051
Controlled Uncontrolled 46.4342(*) 1.29026 .000 43.2840 49.5843
Partly
controlled
19.5553(*) 1.29026 .000 16.4051 22.7054
*  The mean difference is significant at the .05 level.
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CHART 42 : Homogeneous Subsets: PEFR Percentage Tukey HSD
Levels of Asthma
Control
N
Subset for alpha = .05
1 2 3
Uncontrolled 12 54.5487
Partly controlled 12 81.4276
Controlled 16 100.9829
Sig. 1.000 1.000 1.000
Means for groups in homogeneous subsets are displayed.
A Uses Harmonic Mean Sample Size = 13.091.
B  The group sizes are unequal. The harmonic mean of the group sizes
is used. Type I error levels are not guaranteed.
CHART 43 : Oneway:Descriptives
Absolute eosinophil count
N Mean
Std.
Deviation
Std.
Error
95%
Confidence
Interval for
Mean
Minimum Maximum
Lower
Bound
Upper
Bound
uncontrolled 12 1070.00 130.384 37.639 987.16 1152.84 900 1260
Partly
controlled
12 489.17 48.092 13.883 458.61 519.72 380 560
Controlled 16 218.25 54.243 13.561 189.35 247.15 120 300
Total 40 555.05 368.841 58.319 437.09 673.01 120 1260
92
CHART 44 : ANOVA
Absolute eosinophil count
Sum of
Squares df
Mean
Square F Sig.
Between
Groups 5049117.233 2
2524558.61
7
364.05
8 .000
Within
Groups 256576.667 37 6934.505
Total 5305693.900 39
CHART 45 : Post Hoc Tests:Multiple Comparisons     :Dependent
Variable: Absolute eosinophil count ;Tukey HSD
(I) Levels of Asthma
Control
(J) Levels of
Asthma
Control
Mean
Difference
(I-J)
Std.
Error Sig.
95% Confidence
Interval
Lower
Bound
Upper
Bound
Uncontrolled Partly
controlled 580.83(*) 33.996 .000 497.83 663.83
Controlled 851.75(*) 31.801 .000 774.11 929.39
Partly controlled Uncontrolled -580.83(*) 33.996 .000 -663.83 -497.83
Controlled 270.92(*) 31.801 .000 193.28 348.56
Controlled Uncontrolled -851.75(*) 31.801 .000 -929.39 -774.11
Partly
controlled -270.92(*) 31.801 .000 -348.56 -193.28
*  The mean difference is significant at the .05 level.
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CHART 46 : HomogeneousSubsets:Absolute eosinophil count:Tukey
HSD
Levels of Asthma
Control N
Subset for alpha = .05
1 2 3
Controlled 16 218.25
Partly controlled 12 489.17
Uncontrolled 12 1070.00
Sig. 1.000 1.000 1.000
A Uses Harmonic Mean Sample Size = 13.091.b  The group sizes are
unequal. The harmonic mean of the group sizes is used. Type I
error levels are not guaranteed.
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DISCUSSION
Bronchial Asthma is one of the most common disorders of
inflammatory reactions of the respiratory tract, characterized by
breathlessness, wheezing, minimal cough and expectoration. It is true that
allopathic treatment can arrest the disease, but cannot cure completely.
This study was conducted on the patient who attended the Asthma
op in Govt Royapettah Hospital, Kilpauk Medical College, Chennai.  The
patients of 18-75 years were selected for the study. Both the sexes were
included and who belong to different socio-economic groups was taken as
per inclusion criteria. A total of 40 cases were selected minimum of study
was 6months. The statistical analysis made here is based on the data
obtained from 40 cases.
In our study the total number of patients, recruited were 40. There
was almost equal distribution of cases in the three groups with 12(30%)
in uncontrolled, 16(40%) in controlled, and 12(30%) in partly controlled
group as per GINA guidelines.
Sex distribution was almost equal among the subjects with 51%
males and 49% females. Fifty percent of boys were found to be in the
controlled group while the majority of girls (48.6%) were in the
uncontrolled group. Totally 40 patient, male 21, female 19, uncontrolled
asthma 6 for male 6 for female. Partly controlled male 5 ,female7.
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Impression : Absolute eosinophil count more than 450 cells per
cumm seen in 2/3 of patients.(uncontrolled and partially controlled).
Sex wise difference : male - sum of uncontrolled and partly
controlled(11) equal to controlled group(10).Female- sum of uncontrolled
and partly controlled (13) (68.4%)2 times greater than controlled
group(6)(31.6%)
Among the overall sum of uncontrolled and partly controlled
group, females constituted 68.4%, even though the initial sample sizes in
both sexes were comparable.  Males had sum of uncontrolled and partly
controlled constituted 50%. The increased absolute eosinophil count seen
in girls noted in our study needs to be validated by a larger study.
High social economic  and low social economic are equal
disturbance with level of asthma control.
An attempt was made in our study to find the correlation of height,
weight and BMI with absolute eosinophil count.
Our study also find out relation between precipitating factor and
asthma control. Asthma precipitating factors are pet animals,
mosquitorepellants, viralinfections, pollens, smoke.
1) pet animals - 10(3*3*4)(25%)
2) mosquito repellants   - 6(3*1*2)(15%)
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 3) viral infections            - 4(2*1*1)(10%)
 4) pollens                         - 6(3*2*1)(15%)
 5) smoke                          - 1(1*0*0)(2.5%)
Out of 40 patients,
1) 27 had precipitating factors(67.5%),
2) 13 had no precipitating factors(32.5%)
An attempt was made in our study to find the correlation of
hospitalization, emergency visit, x ray chest, ECHO with absolute
eosinophil count.
Fifty seven and half percent (57.5%%) of the asthmatic had
increased eosinophil count(more than 450 cell per cumm) and forty two
and half percent (42.5%) had  normal absolute eosinophil count and p
value 0.000.. Among the 40 asthmatic patients 27(67.5%) had
precipitating factors. So may be allergic asthma patient had increased
absolute eosinophil count compares with non precipitating(non atopic)
factors.
Our study shows that serum absolute eosinophil count  have a
significant impact on asthma control, higher levels correlating with poor
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control so increased dose or frequent steroid inhalation and dose
adjustment, lower absolute eosinophil count well control of asthma.
Lung function as measured by PEFR in our study, showed a
positive correlation with absolute eosinophil count. Patients with high
absolute eosinophil count(more than 450) had a much lower PEFR %,
thus indicating an impaired lung function. High absolute eosinophil count
is generally associated with   inflammatory and infectious diseases thus
impairing pulmonary function and contributing to poor control.
Respiratory tract infections are the commonest trigger for asthma
exacerbation. High absolute eosinophil count is frequently associated
with increased incidence of respiratory tract infections and inflammation.
Thus it is worthwhile to assess the absolute eosinophil count status in all
adults with asthma especially so in the uncontrolled and partly controlled
group. Supplementation of systemic or inhaler steroids decreases the
incidence of respiratory inflammation, thus diminishing the asthma
exacerbations. It is difficult to ascertain that high absolute eosinophil
count alone is responsible for poor asthma control from observational
study like ours. Interventional studies with larger sample size would be
required to prove the cause-effect relationship.
Persistent inflammation is the prime contributory factor for the
symptomatology in uncontrolled asthma.  Measurement of absolute
eosinophil count can be useful in assessing the severity of such
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inflammation. So the evaluation of absolute eosinophil count is a useful
baseline investigation and its serial measurements can be taken as a
marker for adjusting the dose of inhaled steroids.
Thus we infer from our study that there is a positive correlation
between absolute eosinophil count and asthma control.
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STUDY LIMITATION
1. It is a hospital based study with a small catchment area. There has
to be multi-centric randomized control study for validation.
2. Even though there is a strong correlation between the degree of
asthma control and absolute eosinophil count levels, the design of
the study does not allow conclusions about the actual cause- effect
relationship.
3. The adults included in this study are from a large referral centre
and are thus not the actual representation of general population.
4. In our study we did not include the detail history regarding   to find
out the exact factors responsible for increased absolute eosinophil
count
5. Since it was not an interventional study, we did not reassess the
control in our patients after  inhalation steroids and systemic
steroids.
6. Very small member of patient involved in our studySince this is a
time bound study, therefore couldn’t follow the cases for a longer
period. Some good cases couldn’t be considered in this study
because of discontinued treatment in between the study period and
no proper history.
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CONCLUSION
There were a total number of forty  cases taken up at random for
the study. Conclusions were arrived after statistical analysis of patients
with an  bronchial asthma.
The following conclusions are drawn from the study.
1. The prevalence of Allergic bronchial asthma is more in females 19
(47.5%) than in males 21 (52.5%).
2. Bronchial asthma is  equal on both social economic status.
3. Absolute eosinophil count in majority of the cases 23 (57.5%) had
increase absolute eosinophil count more than 450 cells/mm3
4. Our study shows that serum absolute eosinophil count  have a
significant impact(p value 0.000) on   asthma control, higher levels
correlating with poor control ,so increased dose or frequent steroid
inhalation and dose adjustment, lower absolute eosinophil count
well control of asthma.
5. Our study show fifty seven and half percent (57.5%) of the
asthmatic had increased eosinophil count and forty two and half
percent (42.5%) had  normal absolute eosinophil count.. Among
the 40 asthmatic patients 27(67.5%) had precipitating factors.so
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may be allergic asthma patient had increased absolute eosinophil
count compares with non precipitating(non atopic) factors.
6. It is the assessment of susceptibility and sensitivity, which
determines potency selection and its repetition.
7. The disease intensity of scores used for the assessment of effect of
treatment showed significant improvement after the treatment.
8. A detailed case taking and evaluation is necessary for the
management in these cases.
9. Creating awareness and promoting knowledge education, among
the patients and their families is also vital for the proper
implementation of the treatment.
10. Measurement of absolute eosinophil count can be useful in
assessing the severity of such inflammation. So the evaluation of
absolute eosinophil count is a useful baseline investigation and its
serial measurements can be taken as a marker for adjusting the
dose of inhaled steroids.
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RECOMMENDATIONS
1. It is worthwhile to assess precipitating factor and eosinophil count
in all asthmatic and provide supplementation oral and inhaler
steroids, wherever necessary, in order to improve the control
2. Evaluation of absolute eosinophil count and its serial monitoring
can be used as a reliable marker in assessing asthma control and
adjusting the dosage of inhaled steroids.
3. Bigger sample with extended time of research would provide better
results.
4. It will be always scientific if control (placebo) group would have
been kept simultaneously to verify the effectiveness of treatment.
5. Peak flow meters, spirometry, and Immunoglobin assay, and skin
prick test studies if done simultaneously during the course of study
would provide valuable data regarding the changes taking place in
the drugs.
6. Universal standardized scale should be used, so that evaluation of
outcome of the study would become precise.
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Annexure I
Proforma for asthma control
Name :
Age and sex:
Height:              weight:
Serial no:           PEFR:
Classification
Pre requisite; ( asthma patients age 18 -75 yrs)
CHARACTERISTICS
CONTROLLED
(All of the
following)
PARTLY
CONTROLLED
(Any measure
present)
UNCONTROLLED
Daytime symptoms None (twice or
less/week)
More than
twice/week
Three or more
features of partly
controlled asthma
Limitation of activities None Any
Nocturnal symtoms
/awakenings
None Any
Need for reliever/rescue
treatment
None (twice or
less/week)
More than
twice/week
Lung function (PEF or
FEV1)
Normal <80%predicted
or personal best
Type of control:
Absolute eosinophil count:
111
S.No Name Age Sex
Weight
in kg height
socio
eos inomic
status
hospitali
sation
emergen
cy visit
precipitatin
g factor x ray chest
sputum
microscopic ECHO PEFR
Normal
PEFR
PEFR
Percent
Levels of
Asthma
Control
absolute
eosinop
hil count
1 gokulnath 22 m 45 165cm high 0 0 pet animals normal normal normal 350 344 101.744 controlled 250
2 chithra 32 f 44 146cm high 0 0 pet animals normal eosinophils normal 200 265 75.4717partly controlled 550
3 prashanth 24 m 54 160cm low 0 0 pollens normal normal normal 320 326 98.1595 controlled 275
4 saraswathi 42 f 60 147cm low 0 1 mosquito repellants normal eosinophils normal 203 268 75.7463partly controlled 475
5 vanitha 36 f 55 161cm low 3 2 pollens hyperinflationeosinophils,charcot-leyden crystalsmil  pulmon ry hypertension166 314 52.8662 uncontrolled 1000
6 vignesh 27 m 56 166cm high 1 1 pet animals normal normal normal 350 347 100.865 controlled 300
7 rajendren 54 m 80 173cm low 0 0 nil normal normal normal 372 372 100 controlled 230
8 kavitha 44 f 74 160cm low 0 0 nil normal normal normal 310 311 99.6785 controlled 120
9 bharath 30 m 78 174cm high 1 0 pet animals normal normal normal 378 375 100.8 controlled 235
10 malarkodi 29 f 46 163cm low 3 3 pollens normaleosinophils,charcot-leyden crystalsnormal 170 321 52.9595 uncontrolled 1100
11 harini 22 f 53 156cm high 1 1 pet animals normal osinophil normal 256 298 85.906 partly controlled 520
12 yuvaraj 34 m 60 165cm high 1 0 viral infectins normal normal normal 350 344 101.744 controlled 150
13 balaji 35 m 67 168cm low 1 1 viral infectins normal eosinophil normal 275 354 77.6836partly controlled 470
14 ramesh 47 m 78 172cm low 0 0 nil normal normal normal 370 368 100.543 controlled 200
15 saranya 45 f 56 163cm low 0 0 nil normal normal normal 340 321 105.919 controlled 140
16 vijayabharathi 42 f 65 165cm high 1 0 nil normal eosinophil normal 330 328 100.61 controlled 180
17 prakash 40 m 86 174cm low 3 2 mosquito repellantshyperinflationeosinophils,ch rcot-leyden crystals,curschmann's spiralsmild p lmonary hyperten ion200 375 53.3333 uncontrolled 900
18 asha 30 f 56 160cm low 1 0 nil normal eosinophil normal 265 311 85.209 partly controlled 480
19 evangelene 23 f 50 168cm high 3 2 pet animals normaleo inophils,charcot-leyden crystal,curschmann's spiralsnormal 160 337 47.4777 uncontrolled 1020
20 banumathi 33 f 52 160cm high 1 1 nil normal eosinophils normal 260 311 83.6013partly controlled 475
21 sangeetha 31 f 53 163cm low 2 1 viral infectinshyperinflationeosino phils,curschmann's spiralsild pulmonary hypertension180 321 56.0748 uncontrolled 1200
22 saravanan 46 m 70 173cm low 1 2 mosquito repellantshyperinflationeosinophils,charcot-leyden crystalsmil  pulmon ry hypertension200 372 53.7634 uncontrolled 980
23 begam 45 f 65 161cm low 0 0 nil normal eosinophil normal 320 314 101.911 controlled 267
24 karthick 34 m 78 170cm high 1 0 nil normal normal normal 365 361 101.108 controlled 245
25 saran 20 m 76 172cm high 0 0 pet animals normal normal normal 370 368 100.543 controlled 280
26 peterjohn 45 m 73 168cm high 1 0 nil normal eosinophil normal 355 354 100.282 controlled 200
27 kesavan 35 m 78 173cm high 2 2 mosquito repellantshyperinflationeosinophils,charcot-leyden crystalsnormal 200 372 53.7634 uncontrolled 1250
28 laxmi 40 f 65 166cm high 1 0 mosquito repellants normaleosinophils,charcot-leyden crystalsnormal 335 331 101.208 controlled 250
29 gunasundari 34 f 62 160cm low 3 2 viral infectinshyperinflationeosinophils,charcot-leyden crystalsmil  pulmon ry hypertension200 311 64.3087 uncontrolled 1100
30 karthikeyan 36 m 67 165cm low 0 1 nil normal eosinophils normal 275 344 79.9419partly controlled 560
31 balamurugan 29 m 70 168cm low 1 1 pet animals normal eosinophils normal 180 354 50.8475 uncontrolled 900
32 yuvaraj 34 m 72 165cm high 2 2 smoke hyperinflationeosinophils,charcot-leyden crystalsnormal 200 344 58.1395 uncontrolled 950
33 subalaxmi 46 f 70 165cm low 1 1 mosquito repellants normal eosinophils normal 330 328 100.61 controlled 170
34 jeevitha 29 f 56 161cm high 2 1 pollens normal eosinophils normal 275 314 87.5796partly controlled 470
35 padma 33 f 60 160cm high 1 1 pollens normal eosinophils normal 265 311 85.209 partly controlled 460
36 nagaraj 52 m 64 165cm low 3 2 pollens hyperinflationeosinophils,charcot-leyden crystalsmil  pulmon ry hypertension180 344 52.3256 uncontrolled 1260
37 sakthivel 41 m 76 170cm high 1 2 nil normal eosinophils normal 290 361 80.3324partly controlled 530
38 swathy 23 f 56 156cm high 3 3 pet animals normaleosinophils,charcot-leyden crystalsnormal 175 298 58.7248 uncontrolled 1180
39 tamilselvan 37 m 70 168cm low 1 2 nil normal eosinophils normal 285 354 80.5085partly controlled 500
40 praveen 31 m 67 165cm high 2 1 pet animals normaleosinophils,charcot-leyden crystalsnormal 275 344 79.9419partly controlled 380
